Concentra Announces Fourth Quarter and Full Year 2024 Results and Closing of Nova Medical Centers Acquisition
3 mars, 22:30
Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its fourth quarter and full year ended December 31, 2024. Additionally, the Company announced the closing of the transaction to acquire U.S. Occmed Holdings, LLC (“Nova Medical Centers” or “Nova”), an occupational health services company with 67 medical centers based in Houston, Texas.
“Concentra had a successful 2024 — a year marked by change with our IPO and separation from Select Medical. We made significant progress on key strategic initiatives and maintained our emphasis on the delivery of high-quality patient care. Our ability to execute on our objectives and the tireless efforts of our colleagues contributed to our favorable 2024 financial outcomes. I am confident in our ability to continue to deliver strong results in 2025,” said Keith Newton, Chief Executive Officer of Concentra.
Matt DiCanio, Concentra’s President & Chief Financial Officer added, “The impact of our expanded footprint in new and existing geographies during 2024 meant it was easier than ever for our clients to do business with us — and patients benefited as demonstrated in high patient satisfaction scores. With a sustained focus on our development pipeline including the integration of recently acquired Nova Medical Centers, we are well positioned for continued growth in 2025.”
Fourth Quarter 2024 Highlights
For the fourth quarter ended December 31, 2024 and 2023:
Revenue of $465.0 million, an increase of 5.5% from $440.7 million in Q4 2023Net Income of $22.8 million, and earnings per share of $0.17 in Q4 2024Adjusted EBITDA of $77.5 million, an increase of 13.6% from $68.3 million in Q4 2023Cash balance at year end of $183.3 million and net leverage of 3.46xPatient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023Revenue per Visit of $145.08, an increase of 5.8% from $137.15 in Q4 2023Total occupational health centers of 552, compared to 544 at the end of Q4 2023Total onsite health clinics of 157, compared to 150 at the end of Q4 2023
Fourth Quarter 2024 Financial Overview
For the fourth quarter ended December 31, 2024, revenue increased 5.5% to $465.0 million, compared to $440.7 million for the same quarter, prior year. Income from operations increased 19.8% to $59.1 million for the fourth quarter ended December 31, 2024, compared to $49.3 million for the same quarter, prior year. Net income was $22.8 million and earnings per common share was $0.17 for the fourth quarter ended December 31, 2024. Adjusted EBITDA increased 13.6% to $77.5 million for the fourth quarter ended December 31, 2024, compared to $68.3 million for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Year to Date December 31, 2024 Financial Overview
For the year ended December 31, 2024, revenue increased 3.4% to $1,900.2 million, compared to $1,838.1 million for the same period, prior year. Income from operations increased 6.0% to $304.8 million for the year ended December 31, 2024, compared to $287.6 million for the same period, prior year. Net income was $171.9 million and earnings per common share was $1.46 for the year ended December 31, 2024. Adjusted EBITDA increased 4.3% to $376.9 million for the year ended December 31, 2024, compared to $361.3 million for the same period, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Balance Sheet
As of December 31, 2024, our balance sheet reflected cash of $183.3 million, total debt of $1,479.0 million and total assets of $2,521.2 million.
Cash Flow
Cash flows provided by operating activities in the fourth quarter ended December 31, 2024 totaled $93.7 million compared to $76.2 million for the same quarter, prior year. During the fourth quarter ended December 31, 2024, capital expenditures totaled $16.7 million, excluding acquisitions.
Nova Acquisition Closing
Effective March 1, 2025, the Company acquired Nova Medical Centers for a purchase price of $265 million, subject to adjustment in accordance with the terms and conditions set forth in the equity purchase agreement.
Concentra is just beginning the process of integrating Nova Medical Centers into its portfolio of medical centers, with the acquisition helping to strengthen the delivery of quality care and exceptional service through greater access, while also resulting in accelerated innovation and enhanced outcomes for patients, customers and employers. With the addition of Nova Medical Centers, we have over 80 years of combined history supporting and providing occupational health services and have expanded to more than 770 occupational health centers and onsite health clinics at employer worksites located across the country.
The transaction was financed using a combination $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Debt Financing
As part of the funding of the Nova transaction, Concentra has concurrently re-priced its Credit Facilities. Inclusive of the $102.1 million add-on, the Term Loan B due 2031 now has a balance of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including a 25-basis point step down at a net leverage ratio of ≤3.25x. And in conjunction with the $50.0 million draw on the revolver to partially fund the Nova transaction, the Revolving Credit Facility has been increased from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid.
Giving effect to the Nova acquisition and debt-refinancing, Concentra’s pro forma net leverage ratio post-transaction is 3.9x, which is in compliance with the financial covenant under the credit agreement. The Company is targeting a net leverage ratio of approximately 3.0x within 18-24 months.
2025 Business Outlook
Concentra’s strong business performance in 2024 positions the Company well for continued growth as reflected in its 2025 financial guidance. For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results:
Revenue of approximately $2.1 billion Adjusted EBITDA in the range of $410 million to $425 million Capital expenditures in the range of $80 million to $90 million Net leverage ratio of approximately 3.5x
A reconciliation of full year 2025 Adjusted EBITDA expectations to net income is presented in table XI of this release.
Dividend
On February 28, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable April 1, 2025, to stockholders of record as of the close of business on March 18, 2025.
There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board of Directors after taking into account various factors, including, but not limited to, the Company’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board of Directors may deem to be relevant.
Company Overview
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 11,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 50,000 patients each day on average across 45 states at our 552 occupational health centers, 157 onsite health clinics at employer worksites, and Concentra Telemed as of December 31, 2024.
Conference Call
Concentra will host a conference call regarding its fourth quarter results and its business outlook on Tuesday, March 4, 2025, at 9:00 am ET. The conference call will be a live webcast and can be accessed at Concentra Group Holdings Parent, Inc.’s website at www.concentra.com and a replay of the webcast will be available shortly after the call through the same link.
For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Concentra Earnings Call Registration to obtain your dial-in number and unique passcode.
* * * * *
Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2025 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
The frequency of work-related injuries and illnesses; The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks; Changes to regulations, new interpretations of existing regulations, or violations of regulations; Cost containment initiatives or state fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors; Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs; Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs; Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers; A security breach of our, or our third-party vendors’, information technology systems which may cause a violation of HIPAA and subject us to potential legal and reputational harm; Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes; Significant legal actions could subject us to substantial uninsured liabilities; Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements; Insurance coverage may not be sufficient to cover losses we may incur; Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities; Our exposure to additional risk due to our reliance on third parties in many aspects of our business; Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting; Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information; Compliance with applicable data interoperability and information blocking rule; Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations; Our ability to adequately protect and enforce our intellectual property and other proprietary rights; Adverse economic conditions in the U.S. or globally; Any negative impact on the global economy and capital markets resulting from other geopolitical tensions; The impact of impairment of our goodwill and other intangible assets; Our ability to maintain satisfactory credit ratings; The effects of the Separation on our business; Our ability to achieve the expected benefits of and successfully execute the Separation and related transactions; Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions; The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic; The loss of key members of our management team; Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of our senior management; Climate change, or legal, regulatory or market measures to address climate change; Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters; and Changes in tax laws or exposures to additional tax liabilities.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.
I. Consolidated Statements of Operations | |||||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | |||||||||||
(In thousands, except per share amounts, unaudited) | |||||||||||
Quarter Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Revenue | $ | 465,041 | $ | 440,740 | 5.5 | % | |||||
Costs and expenses: | |||||||||||
Cost of services, exclusive of depreciation and amortization | 344,851 | 330,923 | 4.2 | ||||||||
General and administrative, exclusive of depreciation and amortization(1) | 45,493 | 42,101 | 8.1 | ||||||||
Depreciation and amortization | 15,610 | 18,499 | (15.6 | ) | |||||||
Total costs and expenses | 405,954 | 391,523 | 3.7 | ||||||||
Other operating income | — | 99 | N/M | ||||||||
Income from operations | 59,087 | 49,316 | 19.8 | ||||||||
Other income and expense: | |||||||||||
Interest expense on related party debt | — | (10,422 | ) | N/M | |||||||
Interest expense | (26,439 | ) | (113 | ) | N/M | ||||||
Other expense | — | (2 | ) | N/M | |||||||
Income before income taxes | 32,648 | 38,779 | (15.8 | ) | |||||||
Income tax expense | 9,848 | 9,923 | (0.8 | ) | |||||||
Net income | 22,800 | 28,856 | (21.0 | ) | |||||||
Less: net income attributable to non-controlling interests | 1,288 | 1,021 | 26.2 | ||||||||
Net income attributable to the Company | $ | 21,512 | $ | 27,835 | (22.7 | )% | |||||
Basic and diluted earnings per common share(2) | $ | 0.17 | $ | 0.27 |
_______________________________________________________________________________
(1) | Includes the transaction services agreement fee of $3.7 million for the fourth quarter ended December 31, 2024 and the shared service fee from related party of $3.6 million for the fourth quarter ended December 31, 2023. | |
(2) | Refer to table III for calculation of earnings per common share. | |
N/M | Not meaningful |
II. Consolidated Statements of Operations | |||||||||||
For the Years Ended December 31, 2024 and 2023 | |||||||||||
(In thousands, except per share amounts, unaudited) | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Revenue | $ | 1,900,192 | $ | 1,838,081 | 3.4 | % | |||||
Costs and expenses: | |||||||||||
Cost of services, exclusive of depreciation and amortization | 1,372,217 | 1,325,649 | 3.5 | ||||||||
General and administrative, exclusive of depreciation and amortization(1) | 156,318 | 151,999 | 2.8 | ||||||||
Depreciation and amortization | 67,178 | 73,051 | (8.0 | ) | |||||||
Total costs and expenses | 1,595,713 | 1,550,699 | 2.9 | ||||||||
Other operating income | 284 | 250 | 13.6 | ||||||||
Income from operations | 304,763 | 287,632 | 6.0 | ||||||||
Other income and expense: | |||||||||||
Equity in losses of unconsolidated subsidiaries | (3,676 | ) | (526 | ) | 598.9 | ||||||
Interest expense on related party debt | (21,980 | ) | (44,253 | ) | N/M | ||||||
Interest expense | (47,714 | ) | (221 | ) | N/M | ||||||
Other expense | — | (2 | ) | N/M | |||||||
Income before income taxes | 231,393 | 242,630 | (4.6 | ) | |||||||
Income tax expense | 59,496 | 57,887 | 2.8 | ||||||||
Net income | 171,897 | 184,743 | (7.0 | ) | |||||||
Less: net income attributable to non-controlling interests | 5,354 | 4,796 | 11.6 | ||||||||
Net income attributable to the Company | $ | 166,543 | $ | 179,947 | (7.4 | )% | |||||
Basic and diluted earnings per common share(2) | $ | 1.46 | $ | 1.73 |
_______________________________________________________________________________
III. Earnings per Share
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, except per share amounts, unaudited)
At December 31, 2024, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the quarter and year ended December 31, 2024, the Company applied the two-class method because its unvested restricted shares were participating securities.
At December 31, 2023, the Company’s capital structure included Class A, B, and C units outstanding. To calculate EPS for the quarter and year ended December 31, 2023, the Company applied the two-class method because its unvested restricted interests and outstanding options were participating securities.
The following table sets forth the net income attributable to the Company, its shares/units outstanding, and its participating shares/units outstanding:
Quarter Ended December 31, | Year Ended December 31, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
(in thousands) | ||||||||||||
Net income | $ | 22,800 | $ | 28,856 | $ | 171,897 | $ | 184,743 | ||||
Less: net income attributable to non-controlling interests | 1,288 | 1,021 | 5,354 | 4,796 | ||||||||
Net income attributable to the Company | 21,512 | 27,835 | 166,543 | 179,947 | ||||||||
Less: distributed and undistributed income attributable to participating securities | 98 | — | 211 | 316 | ||||||||
Distributed and undistributed income attributable to common shares | $ | 21,414 | $ | 27,835 | $ | 166,332 | $ | 179,631 |
The following tables set forth the computation of EPS under the two-class method for the quarters and years ended December 31, 2024 and 2023:
Quarter Ended December 31, 2024 | Year Ended December 31, 2024 | |||||||||||||||
Net Income Allocation | Shares(1) | Basic and Diluted EPS | Net Income Allocation | Shares(1) | Basic and Diluted EPS | |||||||||||
(in thousands, except for per share amounts) | ||||||||||||||||
Common shares | $ | 21,414 | 127,064 | $ | 0.17 | $ | 166,332 | 114,058 | $ | 1.46 | ||||||
Participating securities | 98 | 579 | $ | 0.17 | 211 | 145 | $ | 1.46 | ||||||||
Total Company | $ | 21,512 | $ | 166,543 |
Quarter Ended December 31, 2023 | Year Ended December 31, 2023 | |||||||||||||||
Net Income Allocation | Shares (1)(2) | Basic and Diluted EPS | Net Income Allocation | Shares (1)(2) | Basic and Diluted EPS | |||||||||||
(in thousands, except for per share amounts) | ||||||||||||||||
Outstanding Class A, Class B, and Class C shares | $ | 27,835 | 104,094 | $ | 0.27 | $ | 179,631 | 104,008 | $ | 1.73 | ||||||
Participating securities | — | — | $ | — | 316 | 183 | $ | 1.73 | ||||||||
Total Company | $ | 27,835 | $ | 179,947 |
_______________________________________________________________________________
(1) | Represents the weighted average shares/units outstanding during the period. | |
(2) | The recapitalization of the members units into common shares has been treated as such for earnings per share purposes and has been reflected retrospectively for all periods, along with the one-for-4.295 reverse stock split. |
IV. Consolidated Balance Sheets | ||||||
(In thousands, unaudited) | ||||||
December 31,
| December 31,
| |||||
ASSETS | ||||||
Current assets: | ||||||
Cash | $ | 183,255 | $ | 31,374 | ||
Accounts receivable | 217,719 | 216,194 | ||||
Prepaid income taxes | 1,544 | 7,979 | ||||
Other current assets | 34,689 | 38,871 | ||||
Total current assets | 437,207 | 294,418 | ||||
Operating lease right-of-use assets | 435,595 | 397,852 | ||||
Property and equipment, net | 197,930 | 178,370 | ||||
Goodwill | 1,234,707 | 1,229,745 | ||||
Other identifiable intangible assets, net | 204,725 | 224,769 | ||||
Other assets | 11,000 | 8,406 | ||||
Total assets | $ | 2,521,164 | $ | 2,333,560 | ||
LIABILITIES AND EQUITY | ||||||
Current liabilities: | ||||||
Current operating lease liabilities | $ | 75,442 | $ | 72,946 | ||
Current portion of long-term debt and notes payable | 10,093 | 1,455 | ||||
Accounts payable | 19,752 | 20,413 | ||||
Accrued and other liabilities | 201,899 | 179,820 | ||||
Total current liabilities | 307,186 | 274,634 | ||||
Non-current operating lease liabilities | 396,914 | 357,310 | ||||
Long-term debt, net of current portion | 1,468,917 | 3,291 | ||||
Long-term debt with related party | — | 470,000 | ||||
Non-current deferred tax liability | 25,380 | 23,364 | ||||
Other non-current liabilities | 24,043 | 27,522 | ||||
Total liabilities | 2,222,440 | 1,156,121 | ||||
Redeemable non-controlling interests | 18,013 | 16,477 | ||||
Stockholders’/members’ equity: | ||||||
Members’ contributed capital | — | 470,303 | ||||
Common stock, $0.01 par value, 700,000,000 shares authorized, 128,125,952 shares issued and outstanding at December 31, 2024 | 1,281 | — | ||||
Capital in excess of par | 260,837 | — | ||||
Retained earnings | 13,553 | 685,293 | ||||
Total stockholders’ equity (members’ equity at December 31, 2023) | 275,671 | 1,155,596 | ||||
Non-controlling interests | 5,040 | 5,366 | ||||
Total equity | 280,711 | 1,160,962 | ||||
Total liabilities and equity | $ | 2,521,164 | $ | 2,333,560 |
V. Consolidated Statements of Cash Flows | ||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | ||||||||
(In thousands, unaudited) | ||||||||
Quarter Ended
| ||||||||
2024 | 2023 | |||||||
Operating activities | ||||||||
Net income | $ | 22,800 | $ | 28,856 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 15,610 | 18,499 | ||||||
(Gain) loss on sale of assets | (1 | ) | 1 | |||||
Stock compensation expense | 1,827 | 473 | ||||||
Amortization of debt discount and issuance costs | 958 | — | ||||||
Deferred income taxes | (1,237 | ) | 293 | |||||
Other | 2 | 51 | ||||||
Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
Accounts receivable | 14,481 | 25,390 | ||||||
Other current assets | (8,294 | ) | (12,207 | ) | ||||
Other assets | (176 | ) | 302 | |||||
Accounts payable and accrued liabilities | 47,744 | 14,520 | ||||||
Net cash provided by operating activities | 93,714 | 76,178 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | — | (4,558 | ) | |||||
Purchases of property and equipment | (16,688 | ) | (23,638 | ) | ||||
Proceeds from sale of assets | 2 | 13 | ||||||
Net cash used in investing activities | (16,686 | ) | (28,183 | ) | ||||
Financing activities | ||||||||
Payments on related party revolving promissory note | — | (40,000 | ) | |||||
Payments on term loans | (2,125 | ) | — | |||||
Principal payments on other debt | (2,293 | ) | (1,383 | ) | ||||
Dividends paid to common stockholders | (7,959 | ) | — | |||||
Repurchase of common stock | (15,403 | ) | — | |||||
Distributions to and purchases of non-controlling interests | (1,687 | ) | (1,608 | ) | ||||
(Distributions to) contributions from Select | (1,128 | ) | 2,690 | |||||
Net cash used in financing activities | (30,595 | ) | (40,301 | ) | ||||
Net increase in cash | 46,433 | 7,694 | ||||||
Cash at beginning of period | 136,822 | 23,680 | ||||||
Cash at end of period | $ | 183,255 | $ | 31,374 | ||||
Supplemental information | ||||||||
Cash paid for interest | $ | 15,429 | $ | 10,360 | ||||
Cash paid for taxes | $ | 6,426 | $ | 10,563 | ||||
Non-cash investing and financing activities: | ||||||||
Liabilities for purchases of property and equipment | $ | 1,583 | $ | — |
VI. Consolidated Statements of Cash Flows | ||||||||
For the Years Ended December 31, 2024 and 2023 | ||||||||
(In thousands, unaudited) | ||||||||
Year Ended
| ||||||||
2024 | 2023 | |||||||
Operating activities | ||||||||
Net income | $ | 171,897 | $ | 184,743 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 67,178 | 73,051 | ||||||
Equity in losses of unconsolidated subsidiaries | 3,676 | 526 | ||||||
Loss on sale of assets | 40 | 4 | ||||||
Stock compensation expense | 2,327 | 651 | ||||||
Amortization of debt discount and issuance costs | 1,708 | — | ||||||
Deferred income taxes | (2,396 | ) | (6,286 | ) | ||||
Other | 72 | 327 | ||||||
Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
Accounts receivable | (1,598 | ) | (10,262 | ) | ||||
Other current assets | 4,206 | (20,743 | ) | |||||
Other assets | 2,973 | 2,738 | ||||||
Accounts payable and accrued liabilities | 24,594 | 9,567 | ||||||
Net cash provided by operating activities | 274,677 | 234,316 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | (6,965 | ) | (6,004 | ) | ||||
Acquired customer relationships | — | (4,382 | ) | |||||
Purchases of property and equipment | (64,327 | ) | (64,958 | ) | ||||
Proceeds from sale of assets | 27 | 36 | ||||||
Net cash used in investing activities | (71,265 | ) | (75,308 | ) |
Year Ended
| ||||||||
2024 | 2023 | |||||||
Financing activities | ||||||||
Borrowings from related party revolving promissory note | 10,000 | — | ||||||
Payments on related party revolving promissory note | (480,000 | ) | (160,000 | ) | ||||
Proceeds from term loans, net of issuance costs | 836,697 | — | ||||||
Payments on term loans | (2,125 | ) | — | |||||
Proceeds from 6.875% senior notes, net of issuance costs | 637,337 | — | ||||||
Borrowings of other debt | 8,222 | 5,471 | ||||||
Principal payments on other debt | (10,181 | ) | (7,165 | ) | ||||
Exercise of stock options | — | 3,340 | ||||||
Repurchase of common shares | — | (5,322 | ) | |||||
Dividends paid to common stockholders | (7,959 | ) | — | |||||
Repurchase of common stock | (15,403 | ) | — | |||||
Distributions to and purchases of non-controlling interests | (5,913 | ) | (6,130 | ) | ||||
Proceeds from Initial Public Offering | 511,198 | — | ||||||
Dividend to Select | (1,535,683 | ) | — | |||||
Contributions from (distributions to) Select | 2,279 | 4,515 | ||||||
Net cash used in financing activities | (51,531 | ) | (165,291 | ) | ||||
Net increase (decrease) in cash | 151,881 | (6,283 | ) | |||||
Cash at beginning of period | 31,374 | 37,657 | ||||||
Cash at end of period | $ | 183,255 | $ | 31,374 | ||||
Supplemental information | ||||||||
Cash paid for interest | $ | 49,650 | $ | 44,348 | ||||
Cash paid for taxes | $ | 55,763 | $ | 60,607 | ||||
Non-cash investing and financing activities: | ||||||||
Liabilities for purchases of property and equipment | $ | 5,241 | $ | 5,136 |
VII. Key Statistics | ||||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | ||||||||||
(unaudited) | ||||||||||
Quarter Ended December 31, | ||||||||||
2024 | 2023 | |||||||||
Facility Count | ||||||||||
Number of occupational health centers—start of period | 549 | 539 | ||||||||
Number of occupational health centers acquired | — | 3 | ||||||||
Number of occupational health centers de novos | 3 | 3 | ||||||||
Number of occupational health centers closed/sold | — | (1 | ) | |||||||
Number of occupational health centers—end of period | 552 | 544 | ||||||||
Number of onsite health clinics operated—end of period | 157 | 150 | ||||||||
The following table sets forth operating statistics for our occupation health centers operating segment for the periods presented: | ||||||||||
Quarter Ended December 31, | ||||||||||
2024 | 2023 | % Change | ||||||||
Number of patient visits | ||||||||||
Workers’ compensation | 1,429,344 | 1,391,325 | 2.7 | % | ||||||
Employer services | 1,506,163 | 1,557,969 | (3.3 | )% | ||||||
Consumer health | 59,481 | 61,457 | (3.2 | )% | ||||||
Total | 2,994,988 | 3,010,751 | (0.5 | )% | ||||||
Visits per day volume | ||||||||||
Workers’ compensation | 22,334 | 22,085 | 1.1 | % | ||||||
Employer services | 23,534 | 24,730 | (4.8 | )% | ||||||
Consumer health | 929 | 976 | (4.8 | )% | ||||||
Total(1) | 46,797 | 47,790 | (2.1 | )% | ||||||
Revenue per visit(2) | ||||||||||
Workers’ compensation | $ | 202.28 | $ | 193.69 | 4.4 | % | ||||
Employer services | 91.09 | 86.92 | 4.8 | % | ||||||
Consumer health | 137.72 | 130.90 | 5.2 | % | ||||||
Total | $ | 145.08 | $ | 137.15 | 5.8 | % | ||||
Business Days(3) | 64 | 63 |
_______________________________________________________________________________
(1) | Does not total due to rounding. | |
(2) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments. | |
(3) | Represents the number of days in which normal business operations were conducted during the periods presented. |
VIII. Key Statistics | |||||||||||
For the Years Ended December 31, 2024 and 2023 | |||||||||||
(unaudited) | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | ||||||||||
Facility Counts | |||||||||||
Number of occupational health centers—start of period | 544 | 540 | |||||||||
Number of occupational health centers acquired | 3 | 4 | |||||||||
Number of occupational health centers de novos | 6 | 3 | |||||||||
Number of occupational health centers closed/sold | (1 | ) | (3 | ) | |||||||
Number of occupational health centers—end of period | 552 | 544 | |||||||||
Number of onsite health clinics operated—end of period | 157 | 150 | |||||||||
The following table sets forth operating statistics for our occupation health centers operating segment for the periods presented: | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Number of patient visits | |||||||||||
Workers’ compensation | 5,794,168 | 5,668,042 | 2.2 | % | |||||||
Employer services | 6,596,573 | 6,874,693 | (4.0 | )% | |||||||
Consumer health | 232,762 | 234,897 | (0.9 | )% | |||||||
Total | 12,623,503 | 12,777,632 | (1.2 | )% | |||||||
Visits per day volume | |||||||||||
Workers’ compensation | 22,633 | 22,315 | 1.4 | % | |||||||
Employer services | 25,768 | 27,066 | (4.8 | )% | |||||||
Consumer health | 909 | 925 | (1.7 | )% | |||||||
Total(1) | 49,311 | 50,306 | (2.0 | )% | |||||||
Revenue per visit(2) | |||||||||||
Workers’ compensation | $ | 199.53 | $ | 194.48 | 2.6 | % | |||||
Employer services | 90.36 | 86.44 | 4.5 | % | |||||||
Consumer health | 135.41 | 132.80 | 2.0 | % | |||||||
Total | $ | 141.30 | $ | 135.22 | 4.5 | % | |||||
Business Days(3) | 256 | 254 |
_______________________________________________________________________________
(1) | Does not total due to rounding. | |
(2) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments. | |
(3) | Represents the number of days in which normal business operations were conducted during the periods presented. |
IX. Disaggregated Revenue
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, unaudited)
The following table disaggregates the Company’s revenue for the quarters and years ended December 31, 2024 and 2023:
Quarter Ended
| Year Ended
| ||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||
(in thousands) | |||||||||||
Occupational health centers: | |||||||||||
Workers' compensation | $ | 289,130 | $ | 269,480 | $ | 1,156,082 | $ | 1,102,313 | |||
Employer services | 137,203 | 135,413 | 596,052 | 594,223 | |||||||
Consumer health | 8,192 | 8,044 | 31,519 | 31,194 | |||||||
Other occupational health center revenue | 2,507 | 1,746 | 8,752 | 8,284 | |||||||
Total occupational health center revenue | 437,032 | 414,683 | 1,792,405 | 1,736,014 | |||||||
Onsite health clinics | 17,092 | 15,926 | 64,081 | 60,181 | |||||||
Other | 10,917 | 10,131 | 43,706 | 41,886 | |||||||
Total revenue | $ | 465,041 | $ | 440,740 | $ | 1,900,192 | $ | 1,838,081 |
X. Net Income to Adjusted EBITDA Reconciliation
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, unaudited)
We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies.
We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.
The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA margin and should be referenced when we discuss Adjusted EBITDA, and Adjusted EBITDA margin.
Quarter Ended December 31, | |||||||||||||
2024 | 2023 | ||||||||||||
($ in thousands) | Amount | % of Revenue | Amount | % of Revenue | |||||||||
Reconciliation of Adjusted EBITDA: | |||||||||||||
Net income | $ | 22,800 | 4.9 | % | $ | 28,856 | 6.5 | % | |||||
Add (Subtract): | |||||||||||||
Income tax expense | 9,848 | 2.1 | 9,923 | 2.3 | |||||||||
Interest expense | 26,439 | 5.7 | 113 | — | |||||||||
Interest expense on related party debt | — | — | 10,422 | 2.4 | |||||||||
Other expense | — | — | 2 | — | |||||||||
Stock compensation expense | 1,827 | 0.4 | 473 | 0.1 | |||||||||
Depreciation and amortization | 15,610 | 3.4 | 18,499 | 4.2 | |||||||||
Separation transaction costs(1) | 124 | — | — | — | |||||||||
Nova acquisition costs | 895 | 0.2 | — | — | |||||||||
Adjusted EBITDA | $ | 77,543 | 16.7 | % | $ | 68,288 | 15.5 | % | |||||
Net income margin | 4.9 | % | 6.5 | % | |||||||||
Adjusted EBITDA margin | 16.7 | % | 15.5 | % |
Year Ended December 31, | |||||||||||||
2024 | 2023 | ||||||||||||
($ in thousands) | Amount | % of Revenue | Amount | % of Revenue | |||||||||
Reconciliation of Adjusted EBITDA: | |||||||||||||
Net income | $ | 171,897 | 9.0 | % | $ | 184,743 | 10.1 | % | |||||
Add (Subtract): | |||||||||||||
Income tax expense | 59,496 | 3.1 | 57,887 | 3.1 | |||||||||
Interest expense | 47,714 | 2.5 | 221 | — | |||||||||
Interest expense on related party debt | 21,980 | 1.2 | 44,253 | 2.4 | |||||||||
Equity in losses of unconsolidated subsidiaries | 3,676 | 0.2 | 526 | — | |||||||||
Other expense | — | — | 2 | — | |||||||||
Stock compensation expense | 2,327 | 0.1 | 651 | 0.1 | |||||||||
Depreciation and amortization | 67,178 | 3.6 | 73,051 | 4.0 | |||||||||
Separation transaction costs(1) | 1,693 | 0.1 | — | — | |||||||||
Nova acquisition costs | 895 | — | — | — | |||||||||
Adjusted EBITDA | $ | 376,856 | 19.8 | % | $ | 361,334 | 19.7 | % | |||||
Net income margin | 9.0 | % | 10.1 | % | |||||||||
Adjusted EBITDA margin | 19.8 | % | 19.7 | % |
______________________________________________________________________________
(1) | Separation transaction costs represent incremental consulting, legal, audit-related fees, and non-recurring system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations. |
XI. 2025 Net Income to Adjusted EBITDA Reconciliation
Business Outlook for the Year Ending December 31, 2025
(In millions)
The following is a reconciliation of full year 2025 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure, giving effect to the acquisition of Nova Medical Centers. Refer to table I for discussion of Concentra's use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2025 expectations.
Range | |||||
Low | High | ||||
($ in millions) | |||||
Net income attributable to the Company | $ | 157 | $ | 168 | |
Net income attributable to non-controlling interests | 6 | 6 | |||
Net income | $ | 163 | $ | 174 | |
Income tax expense | 54 | 58 | |||
Interest expense | 111 | 111 | |||
Stock compensation expense | 10 | 10 | |||
Depreciation and amortization | 68 | 68 | |||
Nova acquisition costs | 4 | 4 | |||
Adjusted EBITDA | $ | 410 | $ | 425 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303493739/en/
Concentra Announces Fourth Quarter and Full Year 2024 Results and Closing of Nova Medical Centers Acquisition
3 mars, 22:30
Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its fourth quarter and full year ended December 31, 2024. Additionally, the Company announced the closing of the transaction to acquire U.S. Occmed Holdings, LLC (“Nova Medical Centers” or “Nova”), an occupational health services company with 67 medical centers based in Houston, Texas.
“Concentra had a successful 2024 — a year marked by change with our IPO and separation from Select Medical. We made significant progress on key strategic initiatives and maintained our emphasis on the delivery of high-quality patient care. Our ability to execute on our objectives and the tireless efforts of our colleagues contributed to our favorable 2024 financial outcomes. I am confident in our ability to continue to deliver strong results in 2025,” said Keith Newton, Chief Executive Officer of Concentra.
Matt DiCanio, Concentra’s President & Chief Financial Officer added, “The impact of our expanded footprint in new and existing geographies during 2024 meant it was easier than ever for our clients to do business with us — and patients benefited as demonstrated in high patient satisfaction scores. With a sustained focus on our development pipeline including the integration of recently acquired Nova Medical Centers, we are well positioned for continued growth in 2025.”
Fourth Quarter 2024 Highlights
For the fourth quarter ended December 31, 2024 and 2023:
Revenue of $465.0 million, an increase of 5.5% from $440.7 million in Q4 2023Net Income of $22.8 million, and earnings per share of $0.17 in Q4 2024Adjusted EBITDA of $77.5 million, an increase of 13.6% from $68.3 million in Q4 2023Cash balance at year end of $183.3 million and net leverage of 3.46xPatient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023Revenue per Visit of $145.08, an increase of 5.8% from $137.15 in Q4 2023Total occupational health centers of 552, compared to 544 at the end of Q4 2023Total onsite health clinics of 157, compared to 150 at the end of Q4 2023
Fourth Quarter 2024 Financial Overview
For the fourth quarter ended December 31, 2024, revenue increased 5.5% to $465.0 million, compared to $440.7 million for the same quarter, prior year. Income from operations increased 19.8% to $59.1 million for the fourth quarter ended December 31, 2024, compared to $49.3 million for the same quarter, prior year. Net income was $22.8 million and earnings per common share was $0.17 for the fourth quarter ended December 31, 2024. Adjusted EBITDA increased 13.6% to $77.5 million for the fourth quarter ended December 31, 2024, compared to $68.3 million for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Year to Date December 31, 2024 Financial Overview
For the year ended December 31, 2024, revenue increased 3.4% to $1,900.2 million, compared to $1,838.1 million for the same period, prior year. Income from operations increased 6.0% to $304.8 million for the year ended December 31, 2024, compared to $287.6 million for the same period, prior year. Net income was $171.9 million and earnings per common share was $1.46 for the year ended December 31, 2024. Adjusted EBITDA increased 4.3% to $376.9 million for the year ended December 31, 2024, compared to $361.3 million for the same period, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release.
Balance Sheet
As of December 31, 2024, our balance sheet reflected cash of $183.3 million, total debt of $1,479.0 million and total assets of $2,521.2 million.
Cash Flow
Cash flows provided by operating activities in the fourth quarter ended December 31, 2024 totaled $93.7 million compared to $76.2 million for the same quarter, prior year. During the fourth quarter ended December 31, 2024, capital expenditures totaled $16.7 million, excluding acquisitions.
Nova Acquisition Closing
Effective March 1, 2025, the Company acquired Nova Medical Centers for a purchase price of $265 million, subject to adjustment in accordance with the terms and conditions set forth in the equity purchase agreement.
Concentra is just beginning the process of integrating Nova Medical Centers into its portfolio of medical centers, with the acquisition helping to strengthen the delivery of quality care and exceptional service through greater access, while also resulting in accelerated innovation and enhanced outcomes for patients, customers and employers. With the addition of Nova Medical Centers, we have over 80 years of combined history supporting and providing occupational health services and have expanded to more than 770 occupational health centers and onsite health clinics at employer worksites located across the country.
The transaction was financed using a combination $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Debt Financing
As part of the funding of the Nova transaction, Concentra has concurrently re-priced its Credit Facilities. Inclusive of the $102.1 million add-on, the Term Loan B due 2031 now has a balance of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including a 25-basis point step down at a net leverage ratio of ≤3.25x. And in conjunction with the $50.0 million draw on the revolver to partially fund the Nova transaction, the Revolving Credit Facility has been increased from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid.
Giving effect to the Nova acquisition and debt-refinancing, Concentra’s pro forma net leverage ratio post-transaction is 3.9x, which is in compliance with the financial covenant under the credit agreement. The Company is targeting a net leverage ratio of approximately 3.0x within 18-24 months.
2025 Business Outlook
Concentra’s strong business performance in 2024 positions the Company well for continued growth as reflected in its 2025 financial guidance. For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results:
Revenue of approximately $2.1 billion Adjusted EBITDA in the range of $410 million to $425 million Capital expenditures in the range of $80 million to $90 million Net leverage ratio of approximately 3.5x
A reconciliation of full year 2025 Adjusted EBITDA expectations to net income is presented in table XI of this release.
Dividend
On February 28, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable April 1, 2025, to stockholders of record as of the close of business on March 18, 2025.
There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board of Directors after taking into account various factors, including, but not limited to, the Company’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board of Directors may deem to be relevant.
Company Overview
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 11,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 50,000 patients each day on average across 45 states at our 552 occupational health centers, 157 onsite health clinics at employer worksites, and Concentra Telemed as of December 31, 2024.
Conference Call
Concentra will host a conference call regarding its fourth quarter results and its business outlook on Tuesday, March 4, 2025, at 9:00 am ET. The conference call will be a live webcast and can be accessed at Concentra Group Holdings Parent, Inc.’s website at www.concentra.com and a replay of the webcast will be available shortly after the call through the same link.
For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Concentra Earnings Call Registration to obtain your dial-in number and unique passcode.
* * * * *
Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2025 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
The frequency of work-related injuries and illnesses; The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks; Changes to regulations, new interpretations of existing regulations, or violations of regulations; Cost containment initiatives or state fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors; Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs; Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs; Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers; A security breach of our, or our third-party vendors’, information technology systems which may cause a violation of HIPAA and subject us to potential legal and reputational harm; Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes; Significant legal actions could subject us to substantial uninsured liabilities; Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements; Insurance coverage may not be sufficient to cover losses we may incur; Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities; Our exposure to additional risk due to our reliance on third parties in many aspects of our business; Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting; Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information; Compliance with applicable data interoperability and information blocking rule; Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations; Our ability to adequately protect and enforce our intellectual property and other proprietary rights; Adverse economic conditions in the U.S. or globally; Any negative impact on the global economy and capital markets resulting from other geopolitical tensions; The impact of impairment of our goodwill and other intangible assets; Our ability to maintain satisfactory credit ratings; The effects of the Separation on our business; Our ability to achieve the expected benefits of and successfully execute the Separation and related transactions; Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions; The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic; The loss of key members of our management team; Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of our senior management; Climate change, or legal, regulatory or market measures to address climate change; Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters; and Changes in tax laws or exposures to additional tax liabilities.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.
I. Consolidated Statements of Operations | |||||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | |||||||||||
(In thousands, except per share amounts, unaudited) | |||||||||||
Quarter Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Revenue | $ | 465,041 | $ | 440,740 | 5.5 | % | |||||
Costs and expenses: | |||||||||||
Cost of services, exclusive of depreciation and amortization | 344,851 | 330,923 | 4.2 | ||||||||
General and administrative, exclusive of depreciation and amortization(1) | 45,493 | 42,101 | 8.1 | ||||||||
Depreciation and amortization | 15,610 | 18,499 | (15.6 | ) | |||||||
Total costs and expenses | 405,954 | 391,523 | 3.7 | ||||||||
Other operating income | — | 99 | N/M | ||||||||
Income from operations | 59,087 | 49,316 | 19.8 | ||||||||
Other income and expense: | |||||||||||
Interest expense on related party debt | — | (10,422 | ) | N/M | |||||||
Interest expense | (26,439 | ) | (113 | ) | N/M | ||||||
Other expense | — | (2 | ) | N/M | |||||||
Income before income taxes | 32,648 | 38,779 | (15.8 | ) | |||||||
Income tax expense | 9,848 | 9,923 | (0.8 | ) | |||||||
Net income | 22,800 | 28,856 | (21.0 | ) | |||||||
Less: net income attributable to non-controlling interests | 1,288 | 1,021 | 26.2 | ||||||||
Net income attributable to the Company | $ | 21,512 | $ | 27,835 | (22.7 | )% | |||||
Basic and diluted earnings per common share(2) | $ | 0.17 | $ | 0.27 |
_______________________________________________________________________________
(1) | Includes the transaction services agreement fee of $3.7 million for the fourth quarter ended December 31, 2024 and the shared service fee from related party of $3.6 million for the fourth quarter ended December 31, 2023. | |
(2) | Refer to table III for calculation of earnings per common share. | |
N/M | Not meaningful |
II. Consolidated Statements of Operations | |||||||||||
For the Years Ended December 31, 2024 and 2023 | |||||||||||
(In thousands, except per share amounts, unaudited) | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Revenue | $ | 1,900,192 | $ | 1,838,081 | 3.4 | % | |||||
Costs and expenses: | |||||||||||
Cost of services, exclusive of depreciation and amortization | 1,372,217 | 1,325,649 | 3.5 | ||||||||
General and administrative, exclusive of depreciation and amortization(1) | 156,318 | 151,999 | 2.8 | ||||||||
Depreciation and amortization | 67,178 | 73,051 | (8.0 | ) | |||||||
Total costs and expenses | 1,595,713 | 1,550,699 | 2.9 | ||||||||
Other operating income | 284 | 250 | 13.6 | ||||||||
Income from operations | 304,763 | 287,632 | 6.0 | ||||||||
Other income and expense: | |||||||||||
Equity in losses of unconsolidated subsidiaries | (3,676 | ) | (526 | ) | 598.9 | ||||||
Interest expense on related party debt | (21,980 | ) | (44,253 | ) | N/M | ||||||
Interest expense | (47,714 | ) | (221 | ) | N/M | ||||||
Other expense | — | (2 | ) | N/M | |||||||
Income before income taxes | 231,393 | 242,630 | (4.6 | ) | |||||||
Income tax expense | 59,496 | 57,887 | 2.8 | ||||||||
Net income | 171,897 | 184,743 | (7.0 | ) | |||||||
Less: net income attributable to non-controlling interests | 5,354 | 4,796 | 11.6 | ||||||||
Net income attributable to the Company | $ | 166,543 | $ | 179,947 | (7.4 | )% | |||||
Basic and diluted earnings per common share(2) | $ | 1.46 | $ | 1.73 |
_______________________________________________________________________________
III. Earnings per Share
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, except per share amounts, unaudited)
At December 31, 2024, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the quarter and year ended December 31, 2024, the Company applied the two-class method because its unvested restricted shares were participating securities.
At December 31, 2023, the Company’s capital structure included Class A, B, and C units outstanding. To calculate EPS for the quarter and year ended December 31, 2023, the Company applied the two-class method because its unvested restricted interests and outstanding options were participating securities.
The following table sets forth the net income attributable to the Company, its shares/units outstanding, and its participating shares/units outstanding:
Quarter Ended December 31, | Year Ended December 31, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
(in thousands) | ||||||||||||
Net income | $ | 22,800 | $ | 28,856 | $ | 171,897 | $ | 184,743 | ||||
Less: net income attributable to non-controlling interests | 1,288 | 1,021 | 5,354 | 4,796 | ||||||||
Net income attributable to the Company | 21,512 | 27,835 | 166,543 | 179,947 | ||||||||
Less: distributed and undistributed income attributable to participating securities | 98 | — | 211 | 316 | ||||||||
Distributed and undistributed income attributable to common shares | $ | 21,414 | $ | 27,835 | $ | 166,332 | $ | 179,631 |
The following tables set forth the computation of EPS under the two-class method for the quarters and years ended December 31, 2024 and 2023:
Quarter Ended December 31, 2024 | Year Ended December 31, 2024 | |||||||||||||||
Net Income Allocation | Shares(1) | Basic and Diluted EPS | Net Income Allocation | Shares(1) | Basic and Diluted EPS | |||||||||||
(in thousands, except for per share amounts) | ||||||||||||||||
Common shares | $ | 21,414 | 127,064 | $ | 0.17 | $ | 166,332 | 114,058 | $ | 1.46 | ||||||
Participating securities | 98 | 579 | $ | 0.17 | 211 | 145 | $ | 1.46 | ||||||||
Total Company | $ | 21,512 | $ | 166,543 |
Quarter Ended December 31, 2023 | Year Ended December 31, 2023 | |||||||||||||||
Net Income Allocation | Shares (1)(2) | Basic and Diluted EPS | Net Income Allocation | Shares (1)(2) | Basic and Diluted EPS | |||||||||||
(in thousands, except for per share amounts) | ||||||||||||||||
Outstanding Class A, Class B, and Class C shares | $ | 27,835 | 104,094 | $ | 0.27 | $ | 179,631 | 104,008 | $ | 1.73 | ||||||
Participating securities | — | — | $ | — | 316 | 183 | $ | 1.73 | ||||||||
Total Company | $ | 27,835 | $ | 179,947 |
_______________________________________________________________________________
(1) | Represents the weighted average shares/units outstanding during the period. | |
(2) | The recapitalization of the members units into common shares has been treated as such for earnings per share purposes and has been reflected retrospectively for all periods, along with the one-for-4.295 reverse stock split. |
IV. Consolidated Balance Sheets | ||||||
(In thousands, unaudited) | ||||||
December 31,
| December 31,
| |||||
ASSETS | ||||||
Current assets: | ||||||
Cash | $ | 183,255 | $ | 31,374 | ||
Accounts receivable | 217,719 | 216,194 | ||||
Prepaid income taxes | 1,544 | 7,979 | ||||
Other current assets | 34,689 | 38,871 | ||||
Total current assets | 437,207 | 294,418 | ||||
Operating lease right-of-use assets | 435,595 | 397,852 | ||||
Property and equipment, net | 197,930 | 178,370 | ||||
Goodwill | 1,234,707 | 1,229,745 | ||||
Other identifiable intangible assets, net | 204,725 | 224,769 | ||||
Other assets | 11,000 | 8,406 | ||||
Total assets | $ | 2,521,164 | $ | 2,333,560 | ||
LIABILITIES AND EQUITY | ||||||
Current liabilities: | ||||||
Current operating lease liabilities | $ | 75,442 | $ | 72,946 | ||
Current portion of long-term debt and notes payable | 10,093 | 1,455 | ||||
Accounts payable | 19,752 | 20,413 | ||||
Accrued and other liabilities | 201,899 | 179,820 | ||||
Total current liabilities | 307,186 | 274,634 | ||||
Non-current operating lease liabilities | 396,914 | 357,310 | ||||
Long-term debt, net of current portion | 1,468,917 | 3,291 | ||||
Long-term debt with related party | — | 470,000 | ||||
Non-current deferred tax liability | 25,380 | 23,364 | ||||
Other non-current liabilities | 24,043 | 27,522 | ||||
Total liabilities | 2,222,440 | 1,156,121 | ||||
Redeemable non-controlling interests | 18,013 | 16,477 | ||||
Stockholders’/members’ equity: | ||||||
Members’ contributed capital | — | 470,303 | ||||
Common stock, $0.01 par value, 700,000,000 shares authorized, 128,125,952 shares issued and outstanding at December 31, 2024 | 1,281 | — | ||||
Capital in excess of par | 260,837 | — | ||||
Retained earnings | 13,553 | 685,293 | ||||
Total stockholders’ equity (members’ equity at December 31, 2023) | 275,671 | 1,155,596 | ||||
Non-controlling interests | 5,040 | 5,366 | ||||
Total equity | 280,711 | 1,160,962 | ||||
Total liabilities and equity | $ | 2,521,164 | $ | 2,333,560 |
V. Consolidated Statements of Cash Flows | ||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | ||||||||
(In thousands, unaudited) | ||||||||
Quarter Ended
| ||||||||
2024 | 2023 | |||||||
Operating activities | ||||||||
Net income | $ | 22,800 | $ | 28,856 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 15,610 | 18,499 | ||||||
(Gain) loss on sale of assets | (1 | ) | 1 | |||||
Stock compensation expense | 1,827 | 473 | ||||||
Amortization of debt discount and issuance costs | 958 | — | ||||||
Deferred income taxes | (1,237 | ) | 293 | |||||
Other | 2 | 51 | ||||||
Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
Accounts receivable | 14,481 | 25,390 | ||||||
Other current assets | (8,294 | ) | (12,207 | ) | ||||
Other assets | (176 | ) | 302 | |||||
Accounts payable and accrued liabilities | 47,744 | 14,520 | ||||||
Net cash provided by operating activities | 93,714 | 76,178 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | — | (4,558 | ) | |||||
Purchases of property and equipment | (16,688 | ) | (23,638 | ) | ||||
Proceeds from sale of assets | 2 | 13 | ||||||
Net cash used in investing activities | (16,686 | ) | (28,183 | ) | ||||
Financing activities | ||||||||
Payments on related party revolving promissory note | — | (40,000 | ) | |||||
Payments on term loans | (2,125 | ) | — | |||||
Principal payments on other debt | (2,293 | ) | (1,383 | ) | ||||
Dividends paid to common stockholders | (7,959 | ) | — | |||||
Repurchase of common stock | (15,403 | ) | — | |||||
Distributions to and purchases of non-controlling interests | (1,687 | ) | (1,608 | ) | ||||
(Distributions to) contributions from Select | (1,128 | ) | 2,690 | |||||
Net cash used in financing activities | (30,595 | ) | (40,301 | ) | ||||
Net increase in cash | 46,433 | 7,694 | ||||||
Cash at beginning of period | 136,822 | 23,680 | ||||||
Cash at end of period | $ | 183,255 | $ | 31,374 | ||||
Supplemental information | ||||||||
Cash paid for interest | $ | 15,429 | $ | 10,360 | ||||
Cash paid for taxes | $ | 6,426 | $ | 10,563 | ||||
Non-cash investing and financing activities: | ||||||||
Liabilities for purchases of property and equipment | $ | 1,583 | $ | — |
VI. Consolidated Statements of Cash Flows | ||||||||
For the Years Ended December 31, 2024 and 2023 | ||||||||
(In thousands, unaudited) | ||||||||
Year Ended
| ||||||||
2024 | 2023 | |||||||
Operating activities | ||||||||
Net income | $ | 171,897 | $ | 184,743 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 67,178 | 73,051 | ||||||
Equity in losses of unconsolidated subsidiaries | 3,676 | 526 | ||||||
Loss on sale of assets | 40 | 4 | ||||||
Stock compensation expense | 2,327 | 651 | ||||||
Amortization of debt discount and issuance costs | 1,708 | — | ||||||
Deferred income taxes | (2,396 | ) | (6,286 | ) | ||||
Other | 72 | 327 | ||||||
Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
Accounts receivable | (1,598 | ) | (10,262 | ) | ||||
Other current assets | 4,206 | (20,743 | ) | |||||
Other assets | 2,973 | 2,738 | ||||||
Accounts payable and accrued liabilities | 24,594 | 9,567 | ||||||
Net cash provided by operating activities | 274,677 | 234,316 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | (6,965 | ) | (6,004 | ) | ||||
Acquired customer relationships | — | (4,382 | ) | |||||
Purchases of property and equipment | (64,327 | ) | (64,958 | ) | ||||
Proceeds from sale of assets | 27 | 36 | ||||||
Net cash used in investing activities | (71,265 | ) | (75,308 | ) |
Year Ended
| ||||||||
2024 | 2023 | |||||||
Financing activities | ||||||||
Borrowings from related party revolving promissory note | 10,000 | — | ||||||
Payments on related party revolving promissory note | (480,000 | ) | (160,000 | ) | ||||
Proceeds from term loans, net of issuance costs | 836,697 | — | ||||||
Payments on term loans | (2,125 | ) | — | |||||
Proceeds from 6.875% senior notes, net of issuance costs | 637,337 | — | ||||||
Borrowings of other debt | 8,222 | 5,471 | ||||||
Principal payments on other debt | (10,181 | ) | (7,165 | ) | ||||
Exercise of stock options | — | 3,340 | ||||||
Repurchase of common shares | — | (5,322 | ) | |||||
Dividends paid to common stockholders | (7,959 | ) | — | |||||
Repurchase of common stock | (15,403 | ) | — | |||||
Distributions to and purchases of non-controlling interests | (5,913 | ) | (6,130 | ) | ||||
Proceeds from Initial Public Offering | 511,198 | — | ||||||
Dividend to Select | (1,535,683 | ) | — | |||||
Contributions from (distributions to) Select | 2,279 | 4,515 | ||||||
Net cash used in financing activities | (51,531 | ) | (165,291 | ) | ||||
Net increase (decrease) in cash | 151,881 | (6,283 | ) | |||||
Cash at beginning of period | 31,374 | 37,657 | ||||||
Cash at end of period | $ | 183,255 | $ | 31,374 | ||||
Supplemental information | ||||||||
Cash paid for interest | $ | 49,650 | $ | 44,348 | ||||
Cash paid for taxes | $ | 55,763 | $ | 60,607 | ||||
Non-cash investing and financing activities: | ||||||||
Liabilities for purchases of property and equipment | $ | 5,241 | $ | 5,136 |
VII. Key Statistics | ||||||||||
For the Fourth Quarters Ended December 31, 2024 and 2023 | ||||||||||
(unaudited) | ||||||||||
Quarter Ended December 31, | ||||||||||
2024 | 2023 | |||||||||
Facility Count | ||||||||||
Number of occupational health centers—start of period | 549 | 539 | ||||||||
Number of occupational health centers acquired | — | 3 | ||||||||
Number of occupational health centers de novos | 3 | 3 | ||||||||
Number of occupational health centers closed/sold | — | (1 | ) | |||||||
Number of occupational health centers—end of period | 552 | 544 | ||||||||
Number of onsite health clinics operated—end of period | 157 | 150 | ||||||||
The following table sets forth operating statistics for our occupation health centers operating segment for the periods presented: | ||||||||||
Quarter Ended December 31, | ||||||||||
2024 | 2023 | % Change | ||||||||
Number of patient visits | ||||||||||
Workers’ compensation | 1,429,344 | 1,391,325 | 2.7 | % | ||||||
Employer services | 1,506,163 | 1,557,969 | (3.3 | )% | ||||||
Consumer health | 59,481 | 61,457 | (3.2 | )% | ||||||
Total | 2,994,988 | 3,010,751 | (0.5 | )% | ||||||
Visits per day volume | ||||||||||
Workers’ compensation | 22,334 | 22,085 | 1.1 | % | ||||||
Employer services | 23,534 | 24,730 | (4.8 | )% | ||||||
Consumer health | 929 | 976 | (4.8 | )% | ||||||
Total(1) | 46,797 | 47,790 | (2.1 | )% | ||||||
Revenue per visit(2) | ||||||||||
Workers’ compensation | $ | 202.28 | $ | 193.69 | 4.4 | % | ||||
Employer services | 91.09 | 86.92 | 4.8 | % | ||||||
Consumer health | 137.72 | 130.90 | 5.2 | % | ||||||
Total | $ | 145.08 | $ | 137.15 | 5.8 | % | ||||
Business Days(3) | 64 | 63 |
_______________________________________________________________________________
(1) | Does not total due to rounding. | |
(2) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments. | |
(3) | Represents the number of days in which normal business operations were conducted during the periods presented. |
VIII. Key Statistics | |||||||||||
For the Years Ended December 31, 2024 and 2023 | |||||||||||
(unaudited) | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | ||||||||||
Facility Counts | |||||||||||
Number of occupational health centers—start of period | 544 | 540 | |||||||||
Number of occupational health centers acquired | 3 | 4 | |||||||||
Number of occupational health centers de novos | 6 | 3 | |||||||||
Number of occupational health centers closed/sold | (1 | ) | (3 | ) | |||||||
Number of occupational health centers—end of period | 552 | 544 | |||||||||
Number of onsite health clinics operated—end of period | 157 | 150 | |||||||||
The following table sets forth operating statistics for our occupation health centers operating segment for the periods presented: | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | % Change | |||||||||
Number of patient visits | |||||||||||
Workers’ compensation | 5,794,168 | 5,668,042 | 2.2 | % | |||||||
Employer services | 6,596,573 | 6,874,693 | (4.0 | )% | |||||||
Consumer health | 232,762 | 234,897 | (0.9 | )% | |||||||
Total | 12,623,503 | 12,777,632 | (1.2 | )% | |||||||
Visits per day volume | |||||||||||
Workers’ compensation | 22,633 | 22,315 | 1.4 | % | |||||||
Employer services | 25,768 | 27,066 | (4.8 | )% | |||||||
Consumer health | 909 | 925 | (1.7 | )% | |||||||
Total(1) | 49,311 | 50,306 | (2.0 | )% | |||||||
Revenue per visit(2) | |||||||||||
Workers’ compensation | $ | 199.53 | $ | 194.48 | 2.6 | % | |||||
Employer services | 90.36 | 86.44 | 4.5 | % | |||||||
Consumer health | 135.41 | 132.80 | 2.0 | % | |||||||
Total | $ | 141.30 | $ | 135.22 | 4.5 | % | |||||
Business Days(3) | 256 | 254 |
_______________________________________________________________________________
(1) | Does not total due to rounding. | |
(2) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments. | |
(3) | Represents the number of days in which normal business operations were conducted during the periods presented. |
IX. Disaggregated Revenue
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, unaudited)
The following table disaggregates the Company’s revenue for the quarters and years ended December 31, 2024 and 2023:
Quarter Ended
| Year Ended
| ||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||
(in thousands) | |||||||||||
Occupational health centers: | |||||||||||
Workers' compensation | $ | 289,130 | $ | 269,480 | $ | 1,156,082 | $ | 1,102,313 | |||
Employer services | 137,203 | 135,413 | 596,052 | 594,223 | |||||||
Consumer health | 8,192 | 8,044 | 31,519 | 31,194 | |||||||
Other occupational health center revenue | 2,507 | 1,746 | 8,752 | 8,284 | |||||||
Total occupational health center revenue | 437,032 | 414,683 | 1,792,405 | 1,736,014 | |||||||
Onsite health clinics | 17,092 | 15,926 | 64,081 | 60,181 | |||||||
Other | 10,917 | 10,131 | 43,706 | 41,886 | |||||||
Total revenue | $ | 465,041 | $ | 440,740 | $ | 1,900,192 | $ | 1,838,081 |
X. Net Income to Adjusted EBITDA Reconciliation
For the Fourth Quarters and Years Ended December 31, 2024 and 2023
(In thousands, unaudited)
We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies.
We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.
The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA margin and should be referenced when we discuss Adjusted EBITDA, and Adjusted EBITDA margin.
Quarter Ended December 31, | |||||||||||||
2024 | 2023 | ||||||||||||
($ in thousands) | Amount | % of Revenue | Amount | % of Revenue | |||||||||
Reconciliation of Adjusted EBITDA: | |||||||||||||
Net income | $ | 22,800 | 4.9 | % | $ | 28,856 | 6.5 | % | |||||
Add (Subtract): | |||||||||||||
Income tax expense | 9,848 | 2.1 | 9,923 | 2.3 | |||||||||
Interest expense | 26,439 | 5.7 | 113 | — | |||||||||
Interest expense on related party debt | — | — | 10,422 | 2.4 | |||||||||
Other expense | — | — | 2 | — | |||||||||
Stock compensation expense | 1,827 | 0.4 | 473 | 0.1 | |||||||||
Depreciation and amortization | 15,610 | 3.4 | 18,499 | 4.2 | |||||||||
Separation transaction costs(1) | 124 | — | — | — | |||||||||
Nova acquisition costs | 895 | 0.2 | — | — | |||||||||
Adjusted EBITDA | $ | 77,543 | 16.7 | % | $ | 68,288 | 15.5 | % | |||||
Net income margin | 4.9 | % | 6.5 | % | |||||||||
Adjusted EBITDA margin | 16.7 | % | 15.5 | % |
Year Ended December 31, | |||||||||||||
2024 | 2023 | ||||||||||||
($ in thousands) | Amount | % of Revenue | Amount | % of Revenue | |||||||||
Reconciliation of Adjusted EBITDA: | |||||||||||||
Net income | $ | 171,897 | 9.0 | % | $ | 184,743 | 10.1 | % | |||||
Add (Subtract): | |||||||||||||
Income tax expense | 59,496 | 3.1 | 57,887 | 3.1 | |||||||||
Interest expense | 47,714 | 2.5 | 221 | — | |||||||||
Interest expense on related party debt | 21,980 | 1.2 | 44,253 | 2.4 | |||||||||
Equity in losses of unconsolidated subsidiaries | 3,676 | 0.2 | 526 | — | |||||||||
Other expense | — | — | 2 | — | |||||||||
Stock compensation expense | 2,327 | 0.1 | 651 | 0.1 | |||||||||
Depreciation and amortization | 67,178 | 3.6 | 73,051 | 4.0 | |||||||||
Separation transaction costs(1) | 1,693 | 0.1 | — | — | |||||||||
Nova acquisition costs | 895 | — | — | — | |||||||||
Adjusted EBITDA | $ | 376,856 | 19.8 | % | $ | 361,334 | 19.7 | % | |||||
Net income margin | 9.0 | % | 10.1 | % | |||||||||
Adjusted EBITDA margin | 19.8 | % | 19.7 | % |
______________________________________________________________________________
(1) | Separation transaction costs represent incremental consulting, legal, audit-related fees, and non-recurring system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations. |
XI. 2025 Net Income to Adjusted EBITDA Reconciliation
Business Outlook for the Year Ending December 31, 2025
(In millions)
The following is a reconciliation of full year 2025 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure, giving effect to the acquisition of Nova Medical Centers. Refer to table I for discussion of Concentra's use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2025 expectations.
Range | |||||
Low | High | ||||
($ in millions) | |||||
Net income attributable to the Company | $ | 157 | $ | 168 | |
Net income attributable to non-controlling interests | 6 | 6 | |||
Net income | $ | 163 | $ | 174 | |
Income tax expense | 54 | 58 | |||
Interest expense | 111 | 111 | |||
Stock compensation expense | 10 | 10 | |||
Depreciation and amortization | 68 | 68 | |||
Nova acquisition costs | 4 | 4 | |||
Adjusted EBITDA | $ | 410 | $ | 425 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303493739/en/
Stockholmsbörsen
-992x558.webp&w=3840&q=75)
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
Stockholmsbörsen
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
